TipRanks
Protagonist Therapeutics (DE:PGF)
BERLIN:PGF
Germany Market
PGF
Protagonist Therapeutics
RESEARCH TOOLSreports

Protagonist Therapeutics (PGF) Stock News & Sentiment

1 Followers
Protagonist Therapeutics: Buy Rating Reiterated as Mimrylo Approval De-Risks Lead Asset; $186 Price Target Unchanged
Premium
Ratings
Protagonist Therapeutics: Buy Rating Reiterated as Mimrylo Approval De-Risks Lead Asset; $186 Price Target Unchanged
16d ago
PTGX
Protagonist Therapeutics: Rusfertide Approval and Partnered Pipeline Underpin Buy Rating, $173 Price Target Reaffirmed
Premium
Ratings
Protagonist Therapeutics: Rusfertide Approval and Partnered Pipeline Underpin Buy Rating, $173 Price Target Reaffirmed
17d ago
PTGX
Protagonist Therapeutics: Emerging Multi-Asset Revenue Streams and Robust Pipeline Drive Buy Rating Ahead of Rusfertide Approval
Premium
Ratings
Protagonist Therapeutics: Emerging Multi-Asset Revenue Streams and Robust Pipeline Drive Buy Rating Ahead of Rusfertide Approval
1M ago
PTGX
Protagonist Therapeutics: Diversified Pipeline Progress and Strong Cash Position Drive Buy Rating and Price Target Hike from $130 to $175
Premium
Ratings
Protagonist Therapeutics: Diversified Pipeline Progress and Strong Cash Position Drive Buy Rating and Price Target Hike from $130 to $175
1M ago
PTGX
Protagonist Therapeutics Highlights ICOTYDE Launch and Rusfertide Deal
Premium
Company Announcements
Protagonist Therapeutics Highlights ICOTYDE Launch and Rusfertide Deal
1M ago
8K
PTGX
PTGX’s PN-881 Phase 1 Completion: A Quiet Milestone With Big Pipeline Implications
Premium
Company Announcements
PTGX’s PN-881 Phase 1 Completion: A Quiet Milestone With Big Pipeline Implications
1M ago
PTGX
Analyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating
Premium
Ratings
Analyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating
2M ago
PTGX
More DE:PGF News >

PGF News on the Web

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
Insider Monkey
Neutral
Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital
TipRanks News
Bullish
Protagonist Therapeutics price target raised to $180 from $153 at Barclays
TipRanks News
Bullish
Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Protagonist Therapeutics (PTGX)
TipRanks News
Bullish
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), Protagonist Therapeutics (PTGX)
TipRanks News
Bullish
Protagonist Therapeutics price target raised to $182 from $175 at Citi
TipRanks News
Bullish
Protagonist Therapeutics price target raised to $170 from $165 at Citizens
TipRanks News
Bullish
Protagonist Therapeutics: Rusfertide Approval and Partnered Pipeline Underpin Buy Rating, $173 Price Target Reaffirmed
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average6.25 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:PGF’s Media Buzz Sentiment?
Currently, no data Available
What is DE:PGF’s weekly average amount of articles?
In an average week, 6.25 articles about DE:PGF are published.
    What is DE:PGF’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    VCYTVeracyte
    BMYBristol-Myers Squibb
    SLDBSolid Biosciences
    DFTXDefinium Therapeutics
    LHLabcorp Holdings
    Showing the stocks with the most bullish news sentiment over the past week